Fei Liu

List of Publications by Year
in descending order

138	10,839	31976	32842
papers	citations	53 h-index	100 g-index

145	145	145	12392
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Excess folic acid supplementation before and during pregnancy and lactation activates Î²-catenin in the brain of male mouse offspring. Brain Research Bulletin, 2022, 178, 133-143.	3.0	4
2	Nonâ€vitamin K oral anticoagulants versus vitamin K antagonists in post transcatheter aortic valve replacement patients with clinical indication for oral anticoagulation: A metaâ€analysis. Clinical Cardiology, 2022, 45, 401-406.	1.8	5
3	AKT/GSK-3Î² signaling is altered through downregulation of mTOR during cerebral Ischemia/Reperfusion injury. Molecular Biology Reports, 2022, , 1.	2.3	2
4	Does proteopathic tau propagate trans-synaptically in the brain?. Molecular Neurodegeneration, 2022, 17, 21.	10.8	1
5	Cardioprotective effect of rosmarinic acid against myocardial ischaemia/reperfusion injury via suppression of the NF-Î°B inflammatory signalling pathway and ROS production in mice. Pharmaceutical Biology, 2021, 59, 220-229.	2.9	23
6	Vitamin D3 reduces hippocampal NR2A and anxiety in nicotine withdrawal mice. Translational Neuroscience, 2021, 12, 273-281.	1.4	2
7	Seeding-Competent Tau in Gray Matter Versus White Matter of Alzheimerâ€™s Disease Brain. Journal of Alzheimer's Disease, 2021, 79, 1647-1659.	2.6	4
8	Alzheimerâ€™s disease brain contains tau fractions with differential prion-like activities. Acta Neuropathologica Communications, 2021, 9, 28.	5.2	35
9	Dephosphorylation Passivates the Seeding Activity of Oligomeric Tau Derived From Alzheimerâ€™s Brain. Frontiers in Molecular Neuroscience, 2021, 14, 631833.	2.9	9
10	Maternal Nicotine Exposure Alters Hippocampal Microglia Polarization and Promotes Anti-inflammatory Signaling in Juvenile Offspring in Mice. Frontiers in Pharmacology, 2021, 12, 661304.	3.5	13
11	Rats Display Sexual Dimorphism in Phosphorylation of Brain Tau with Age. Journal of Alzheimer's Disease, 2021, 82, 855-869.	2.6	1
12	Phosphorylation of transâ€active response DNAâ€binding proteinâ€of 43ÂkDa promotes its cytoplasmic aggregation and modulates its function in tau mRNA stability and exon 10 alternative splicing. Journal of Neurochemistry, 2021, 158, 766-778.	3.9	6
13	N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-Î± Expressions. Annals of Clinical and Laboratory Science, 2021, 51, 503-511.	0.2	0
14	Resveratrol attenuates doxorubicin-induced cardiotoxicity in rats by up-regulation of vascular endothelial growth factor B. Journal of Nutritional Biochemistry, 2020, 79, 108132.	4.2	37
15	Elevation of casein kinase 1Îµ associated with TDPâ€43 and tau pathologies in Alzheimer's disease. Brain Pathology, 2020, 30, 283-297.	4.1	9
16	Truncation of Tau selectively facilitates its pathological activities. Journal of Biological Chemistry, 2020, 295, 13812-13828.	3.4	54
17	Ex-vivo treatment of allografts using adipose-derived stem cells induced prolonged rejection-free survival in an allogenic hind-limb transplantation model. Annals of Translational Medicine, 2020, 8, 867-867.	1.7	9
18	Effect of Peripheral Insulin Administration on Phosphorylation of Tau in the Brain. Journal of Alzheimer's Disease, 2020, 75, 1377-1390.	2.6	2

#	Article	IF	Citations
19	Expression of Microtubule Associated Protein Tau in Mouse Pancreatic Islets Is Restricted to Autonomic Nerve Fibers. Journal of Alzheimer's Disease, 2020, 75, 1339-1349.	2.6	3
20	Tau in Alzheimerâ€™s Disease: Pathological Alterations and an Attractive Therapeutic Target. Current Medical Science, 2020, 40, 1009-1021.	1.8	16
21	SIRT1 regulates O-GlcNAcylation of tau through OGT. Aging, 2020, 12, 7042-7055.	3.1	17
22	Cyclic AMP-Dependent Protein Kinase Phosphorylates TDP-43 and Modulates Its Function in Tau mRNA Processing. Journal of Alzheimer's Disease, 2019, 70, 1093-1102.	2.6	6
23	Why delay in effective treatment for Alzheimer's disease and related conditions. Progress in Molecular Biology and Translational Science, 2019, 168, 243-256.	1.7	0
24	Plasmodium berghei serine/threonine protein phosphatase PP5 plays a critical role in male gamete fertility. International Journal for Parasitology, 2019, 49, 685-695.	3.1	13
25	Excess Folic Acid Supplementation Before and During Pregnancy and Lactation Activates Fos Gene Expression and Alters Behaviors in Male Mouse Offspring. Frontiers in Neuroscience, 2019, 13, 313.	2.8	21
26	Pathological Tau From Alzheimerâ€™s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo. Frontiers in Aging Neuroscience, 2019, 11, 34.	3.4	85
27	Subacute to chronic Alzheimer-like alterations after controlled cortical impact in human tau transgenic mice. Scientific Reports, 2019, 9, 3789.	3.3	8
28	Pathological Alterations of Tau in Alzheimerâ€™s Disease and 3xTg-AD Mouse Brains. Molecular Neurobiology, 2019, 56, 6168-6183.	4.0	29
29	Conditioned Medium from Adipose-Derived Stem Cell Inhibits Jurkat Cell Proliferation through TGF-Î²1 and p38/MAPK Pathway. Analytical Cellular Pathology, 2019, 2019, 1-6.	1.4	4
30	Pathological Changes of Tau Related to Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 931-944.	3.5	54
31	Maternal Nicotine Exposure During Gestation and Lactation Period Affects Behavior and Hippocampal Neurogenesis in Mouse Offspring. Frontiers in Pharmacology, 2019, 10, 1569.	3.5	10
32	Glycogen synthase kinase-3Î² suppresses the expression of protein phosphatase methylesterase-1 through Î²-catenin. Aging, 2019, 11, 9672-9688.	3.1	6
33	Recent developments with tau-based drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 399-410.	5.0	35
34	Calpain I Activation Causes GLUT3 Proteolysis and Downregulation of O-GlcNAcylation in Alzheimerâ€™s Disease Brain. Journal of Alzheimer's Disease, 2018, 62, 1737-1746.	2.6	23
35	Protein Phosphatase 1 dephosphorylates <scp>TDP</scp>â€43 and suppresses its function in tau exon 10 inclusion. FEBS Letters, 2018, 592, 402-410.	2.8	14
36	O-GlcNAcylation modulates PKA-CREB signaling in a manner specific to PKA catalytic subunit isoforms. Biochemical and Biophysical Research Communications, 2018, 497, 194-199.	2.1	9

#	Article	IF	Citations
37	Mechanism of Tau Hyperphosphorylation Involving Lysosomal Enzyme Asparagine Endopeptidase in a Mouse Model of Brain Ischemia. Journal of Alzheimer's Disease, 2018, 63, 821-833.	2.6	33
38	FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. Cell Death and Disease, 2018, 9, 469.	6.3	33
39	Multifactorial Hypothesis and Multi-Targets for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S107-S117.	2.6	112
40	P3â€183: RELEVANCE OF PHOSPHORYLATION AND TRUNCATION OF TAU TO THE ETIOPATHOGENESIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1137.	0.8	1
41	Rbfox3/NeuN Regulates Alternative Splicing of Tau Exon 10. Journal of Alzheimer's Disease, 2018, 66, 1695-1704.	2.6	3
42	P3â€185: INVOLVEMENT OF ACTIVATION OF ASPARAGINYL ENDOPEPTIDASE IN TAU HYPERPHOSPHORYLATION IN TRAUMATIC BRAIN INJURY. Alzheimer's and Dementia, 2018, 14, P1138.	0.8	0
43	Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 27.	3.4	86
44	Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3â€‰Ã—â€‰Tg-AD mice. Alzheimer's Research and Therapy, 2018, 10, 13.	6.2	73
45	InÂvitro examination of microglia-neuron crosstalk with BV2 cells, and primary cultures of glia and hypothalamic neurons. Heliyon, 2018, 4, e00730.	3.2	8
46	Involvement of Activation of Asparaginyl Endopeptidase in Tau Hyperphosphorylation in Repetitive Mild Traumatic Brain Injury. Journal of Alzheimer's Disease, 2018, 64, 709-722.	2.6	20
47	Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice. Aging, 2018, 10, 2498-2510.	3.1	13
48	Tau passive immunization inhibits not only tau but also Aî² pathology. Alzheimer's Research and Therapy, 2017, 9, 1.	6.2	147
49	Câ€terminal truncation of <scp>GSK</scp>â€3î² enhances its dephosphorylation by <scp>PP</scp>2A. FEBS Letters, 2017, 591, 1053-1063.	2.8	11
50	TDP-43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Research, 2017, 45, 6177-6193.	14.5	45
51	Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. Journal of Biological Chemistry, 2017, 292, 10600-10612.	3.4	63
52	Up-regulation of casein kinase 1îµ is involved in tau pathogenesis in Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13478.	3.3	21
53	O-GlcNAcylation Reduces Ischemia-Reperfusionâ€“Induced Brain Injury. Scientific Reports, 2017, 7, 10686.	3.3	29
54	Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice. Scientific Reports, 2017, 7, 619.	3.3	66

#	Article	IF	Citations
55	SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion. Journal of Alzheimer's Disease, 2017, 61, 561-570.	2.6	10
56	[O2â€“02â€“05]: Câ€TERMINAL TRUNCATION OF GSKâ€3Î² ENHANCES ITS DEPHOSPHORYLATION BY PP2A. Alzheimer's and Dementia, 2017, 13, P553.	0.8	0
57	Intranasal Insulin Prevents Anesthesia-Induced Cognitive Impairment and Chronic Neurobehavioral Changes. Frontiers in Aging Neuroscience, 2017, 9, 136.	3.4	24
58	Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. Frontiers in Aging Neuroscience, 2017, 9, 311.	3.4	40
59	Chemical-sensitive graphene modulator with a memory effect for internet-of-things applications. Microsystems and Nanoengineering, 2016, 2, 16018.	7.0	36
60	O5â€06â€01: TDPâ€43 Suppresses TAU Expression VIA Promoting its Mrna Instability. Alzheimer's and Dementia, 2016, 12, P390.	0.8	0
61	Hyperphosphorylation determines both the spread and the morphology ofÂtau pathology. Alzheimer's and Dementia, 2016, 12, 1066-1077.	0.8	112
62	Oâ€GlcNAcylation: A regulator of tau pathology and neurodegeneration. Alzheimer's and Dementia, 2016, 12, 1078-1089.	0.8	79
63	Resveratrol attenuates myocardial ischemia/reperfusion injury through up-regulation of vascular endothelial growth factor B. Free Radical Biology and Medicine, 2016, 101, 1-9.	2.9	60
64	Oâ€Glc<scp>NA</scp>cylation of protein kinase A catalytic subunits enhances its activity: a mechanism linked to learning and memory deficits in Alzheimer's disease. Aging Cell, 2016, 15, 455-464.	6.7	57
65	Salt-induced aggregation of gold nanoparticles for photoacoustic imaging and photothermal therapy of cancer. Nanoscale, 2016, 8, 4452-4457.	5.6	118
66	Tau and neurodegenerative disease: the story so far. Nature Reviews Neurology, 2016, 12, 15-27.	10.1	603
67	GSK-3Î² is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner. Journal of Alzheimer's Disease, 2015, 49, 365-375.	2.6	24
68	O-GlcNAcylation regulates ischemia-induced neuronal apoptosis through AKT signaling. Scientific Reports, 2015, 5, 14500.	3.3	60
69	Rapid alteration of protein phosphorylation during postmortem: implication in the study of protein phosphorylation. Scientific Reports, 2015, 5, 15709.	3.3	71
70	Image reconstruction for synchronous data acquisition in fluorescence molecular tomography. Journal of X-Ray Science and Technology, 2015, 23, 463-472.	1.0	0
71	O2-12-03: Regulation of alternative splicing of tau exon 10 by dual-specificity tyrosine-phosphorylation-regulated kinase 1A. , 2015, 11, P203-P203.		0
72	Truncation and activation of GSK-3Î² by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. Scientific Reports, 2015, 5, 8187.	3.3	75

#	Article	IF	Citations
73	Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. Journal of Neural Transmission, 2015, 122, 607-617.	2.8	79
74	Division of Labor in an Oligomer of the DEAD-Box RNA Helicase Ded1p. Molecular Cell, 2015, 59, 541-552.	9.7	60
75	Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I. Journal of Biological Chemistry, 2015, 290, 15219-15237.	3.4	51
76	Acceleration of dynamic fluorescence molecular tomography with principal component analysis. Biomedical Optics Express, 2015, 6, 2036.	2.9	8
77	Novel lanthanideâ€“polymer complexes for dye-free dual modal probes for MRI and fluorescence imaging. Polymer Chemistry, 2015, 6, 7949-7957.	3.9	33
78	Fluorescence molecular tomography reconstruction via discrete cosine transform-based regularization. Journal of Biomedical Optics, 2015, 20, 055004.	2.6	25
79	Cross talk between PI3K-AKT-GSK-3Î² and PP2A pathways determines tau hyperphosphorylation. Neurobiology of Aging, 2015, 36, 188-200.	3.1	99
80	In vivo tomographic imaging with fluorescence and MRI using tumor-targeted dual-labeled nanoparticles. International Journal of Nanomedicine, 2014, 9, 33.	6.7	50
81	Luteolin Inhibits Behavioral Sensitization by Blocking Methamphetamine-Induced MAPK Pathway Activation in the Caudate Putamen in Mice. PLoS ONE, 2014, 9, e98981.	2.5	19
82	Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. Frontiers in Aging Neuroscience, 2014, 6, 100.	3.4	41
83	An adaptive support driven reweighted L1-regularization algorithm for fluorescence molecular tomography. Biomedical Optics Express, 2014, 5, 4039.	2.9	21
84	Cytoplasmic Retention of Protein Phosphatase 2A Inhibitor 2 (I2PP2A) Induces Alzheimer-like Abnormal Hyperphosphorylation of Tau. Journal of Biological Chemistry, 2014, 289, 27677-27691.	3.4	59
85	Primed 3D injectable microniches enabling low-dosage cell therapy for critical limb ischemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13511-13516.	7.1	127
86	Enhanced spatial resolution in fluorescence molecular tomography using restarted L1-regularized nonlinear conjugate gradient algorithm. Journal of Biomedical Optics, 2014, 19, 046018.	2.6	39
87	Modified forward model for eliminating the time-varying impact in fluorescence molecular tomography. Journal of Biomedical Optics, 2014, 19, 056012.	2.6	8
88	Cyclic AMP-Dependent Protein Kinase Enhances SC35-Promoted Tau Exon 10 Inclusion. Molecular Neurobiology, 2014, 49, 615-624.	4.0	12
89	Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. Biochemical Pharmacology, 2014, 88, 631-639.	4.4	95
90	Regulation of alternative splicing of tau exon 10. Neuroscience Bulletin, 2014, 30, 367-377.	2.9	80

#	Article	IF	Citations
91	Optimal method for short-term or long-term islet preservation: comparison of islet culture, cold preservation and cryopreservation. Journal of Artificial Organs, 2014, 17, 337-343.	0.9	22
92	Reduced EGFR signaling enhances cartilage destruction in a mouse osteoarthritis model. Bone Research, 2014, 2, 14015.	11.4	47
93	Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study. Journal of Biophotonics, 2014, 7, 889-896.	2.3	2
94	Hyperphosphorylation-Induced Tau Oligomers. Frontiers in Neurology, 2013, 4, 112.	2.4	80
95	CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease. Nucleic Acids Research, 2013, 41, 3240-3256.	14.5	55
96	Activation of Asparaginyl Endopeptidase Leads to Tau Hyperphosphorylation in Alzheimer Disease. Journal of Biological Chemistry, 2013, 288, 17495-17507.	3.4	100
97	Weighted depth compensation algorithm for fluorescence molecular tomography reconstruction. Applied Optics, 2012, 51, 8883.	1.8	7
98	Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion. Journal of Biological Chemistry, 2012, 287, 30497-30506.	3.4	81
99	Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiology of Aging, 2012, 33, 1389-1399.	3.1	50
100	Cyclic AMPâ€dependent protein kinase regulates 9G8â€mediated alternative splicing of tau exon 10. FEBS Letters, 2012, 586, 2239-2244.	2.8	19
101	Diverse regulation of AKT and GSKâ€3Î² by Oâ€GlcNAcylation in various types of cells. FEBS Letters, 2012, 586, 2443-2450.	2.8	36
102	Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation. PLoS ONE, 2012, 7, e35277.	2.5	76
103	Developmental Regulation of Protein O-GlcNAcylation, O-GlcNAc Transferase, and O-GlcNAcase in Mammalian Brain. PLoS ONE, 2012, 7, e43724.	2.5	77
104	Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e51432.	2.5	47
105	Extraction of target fluorescence signal from in vivo background signal using image subtraction algorithm. International Journal of Automation and Computing, 2012, 9, 232-236.	4.5	16
106	Splicing factor SC35 promotes tau expression through stabilization of its mRNA. FEBS Letters, 2011, 585, 875-880.	2.8	21
107	Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I₂^{PP2A}/SET. FEBS Letters, 2011, 585, 2653-2659.	2.8	94
108	Activation of Protein Phosphatase 2B and Hyperphosphorylation of Tau in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 617-627.	2.6	37

#	Article	IF	Citations
109	Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. Journal of Pathology, 2011, 225, 54-62.	4.5	401
110	Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Research, 2011, 39, 6161-6171.	14.5	84
111	Cyclic AMP-dependent Protein Kinase Regulates the Alternative Splicing of Tau Exon 10. Journal of Biological Chemistry, 2011, 286, 14639-14648.	3.4	76
112	Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochemical Society Transactions, 2010, 38, 962-966.	3.4	58
113	A Parallel Excitation Based Fluorescence Molecular Tomography System for Whole-Body Simultaneous Imaging of Small Animals. Annals of Biomedical Engineering, 2010, 38, 3440-3448.	2.5	43
114	PP2A Regulates Tau Phosphorylation Directly and also Indirectly via Activating GSK-3Î². Journal of Alzheimer's Disease, 2010, 19, 1221-1229.	2.6	143
115	Dysregulation of Tau Phosphorylation in Mouse Brain during Excitotoxic Damage. Journal of Alzheimer's Disease, 2009, 17, 531-539.	2.6	65
116	Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain, 2009, 132, 1820-1832.	7.6	350
117	Mechanisms of tau-induced neurodegeneration. Acta Neuropathologica, 2009, 118, 53-69.	7.7	577
118	Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. Journal of Neurochemistry, 2009, 108, 1480-1494.	3.9	153
119	Tau exon 10 alternative splicing and tauopathies. Molecular Neurodegeneration, 2008, 3, 8.	10.8	225
120	Microtubule-associated protein tau in development, degeneration and protection of neurons. Progress in Neurobiology, 2008, 85, 148-175.	5.7	341
121	ATP hydrolysis is required for DEAD-box protein recycling but not for duplex unwinding. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20209-20214.	7.1	213
122	Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB Journal, 2008, 22, 3224-3233.	0.5	210
123	Regulation between Oâ€GlcNAcylation and phosphorylation of neurofilamentâ€M and their dysregulation in Alzheimer disease. FASEB Journal, 2008, 22, 138-145.	0.5	72
124	Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome. Journal of Biological Chemistry, 2008, 283, 28660-28669.	3.4	136
125	Decrease of Protein Phosphatase 2A and its Association with Accumulation and Hyperphosphorylation of Tau in Down Syndrome. Journal of Alzheimer's Disease, 2008, 13, 295-302.	2.6	39
126	Siteâ€specific effects of tau phosphorylation on its microtubule assembly activity and selfâ€aggregation. European Journal of Neuroscience, 2007, 26, 3429-3436.	2.6	172

#	Article	IF	Citations
127	Downâ€regulation of cAMPâ€dependent protein kinase by overâ€activated calpain in Alzheimer disease brain. Journal of Neurochemistry, 2007, 103, 2462-2470.	3.9	123
128	PKA modulates GSK-3Î²- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Letters, 2006, 580, 6269-6274.	2.8	114
129	Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer's Disease: A Therapeutic Target. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-11.	3.0	56
130	Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. European Journal of Neuroscience, 2005, 22, 1942-1950.	2.6	657
131	Truncation and Activation of Calcineurin A by Calpain I in Alzheimer Disease Brain. Journal of Biological Chemistry, 2005, 280, 37755-37762.	3.4	150
132	Dephosphorylation of Tau by Protein Phosphatase 5. Journal of Biological Chemistry, 2005, 280, 1790-1796.	3.4	106
133	Tau pathology in Alzheimer disease and other tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 198-210.	3.8	786
134	Dephosphorylation of microtubuleâ€associated protein tau by protein phosphatase 5. Journal of Neurochemistry, 2004, 88, 298-310.	3.9	66
135	O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10804-10809.	7.1	650
136	Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Letters, 2002, 512, 101-106.	2.8	123
137	Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3Î². FEBS Letters, 2002, 530, 209-214.	2.8	174
138	Tau in Health and Neurodegenerative Diseases. , 0, , .		0